These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26552493)

  • 21. Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.
    Merkies ISJ; Lawo JP; Edelman JM; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Mielke O; Tackenberg B; Léger JM;
    J Peripher Nerv Syst; 2017 Jun; 22(2):149-152. PubMed ID: 28594116
    [No Abstract]   [Full Text] [Related]  

  • 22. Reassessing IVIg therapy in chronic inflammatory demyelinating polyradiculoneuropathy during COVID-19: a chance to verify the need for chronic maintenance therapy.
    Romozzi M; Bisogni G; Sabatelli M; Luigetti M
    Neurol Sci; 2021 Mar; 42(3):787-789. PubMed ID: 33428052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; van den Berg LH; Vermeulen M; Brusse E; Cats EA; van der Kooi AJ; Notermans NC; van der Pol WL; van Schaik IN; van Nes SI; Hop WC; van Doorn PA
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1374-9. PubMed ID: 20587484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of high infusion rate IVIG in CIDP.
    Jiang Y; Mendoza M; Sarpong E; Mannan S; Ng E; Katzberg H; Bril V; Barnett C
    Muscle Nerve; 2020 Nov; 62(5):637-641. PubMed ID: 32785949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical condition of chronic inflammatory demyelinating polyneuropathy (CIDP).
    Phillips LH
    Muscle Nerve; 2009 Apr; 39(4):v-vii. PubMed ID: 19418620
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.
    Lopate G; Pestronk A; Al-Lozi M
    Arch Neurol; 2005 Feb; 62(2):249-54. PubMed ID: 15710853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.
    Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R
    Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy.
    Doneddu PE; Mandia D; Gentile F; Gallia F; Liberatore G; Terenghi F; Ruiz M; Nobile-Orazio E
    J Peripher Nerv Syst; 2020 Sep; 25(3):238-246. PubMed ID: 32470190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasmacytosis is a common immune signature in patients with MMN and CIDP and responds to treatment with IVIg.
    Korporal-Kuhnke M; Haas J; Schwarz A; Jarius S; Wildemann B
    J Neuroimmunol; 2015 Jan; 278():60-8. PubMed ID: 25595253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A women with aplastic anemia developed chronic inflammatory demyelinating polyneuropathy].
    Abe M; Shimizu F; Suzukawa M; Maeda T; Omoto M; Kanda T
    Rinsho Shinkeigaku; 2019 Dec; 59(12):818-822. PubMed ID: 31761833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of IgG levels on the number of natural killer cells and their Fc receptors in chronic inflammatory demyelinating polyradiculoneuropathy.
    Bohn AB; Nederby L; Harbo T; Skovbo A; Vorup-Jensen T; Krog J; Jakobsen J; Hokland ME
    Eur J Neurol; 2011 Jun; 18(6):919-24. PubMed ID: 21219545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy].
    Kanda F; Sekiguchi K; Oishi K; Hamaguchi H; Mitsui S; Kobessho H; Higuchi M; Shirafuji T; Ishihara H
    Rinsho Shinkeigaku; 2006 Mar; 46(3):236-8. PubMed ID: 16642939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome.
    Vina ER; Fang AJ; Wallace DJ; Weisman MH
    Semin Arthritis Rheum; 2005 Dec; 35(3):175-84. PubMed ID: 16325658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
    Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
    Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Home IVIG for CIDP: a focus on patient centred care.
    Katzberg HD; Rasutis V; Bril V
    Can J Neurol Sci; 2013 May; 40(3):384-8. PubMed ID: 23603176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.
    Marsh EA; Hirst CL; Llewelyn JG; Cossburn MD; Reilly MM; Krishnan A; Doran M; Ryan AM; Coles AJ; Jones JL; Robertson NP
    J Neurol; 2010 Jun; 257(6):913-9. PubMed ID: 20049473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
    Boërio D; Créange A; Hogrel JY; Guéguen A; Bertrand D; Lefaucheur JP
    J Neurol Sci; 2010 May; 292(1-2):63-71. PubMed ID: 20219211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in spatiotemporal gait parameters following intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.
    Vo ML; Chin RL; Miranda C; Latov N
    Muscle Nerve; 2017 Oct; 56(4):732-736. PubMed ID: 28085193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP.
    Iijima M; Tomita M; Morozumi S; Kawagashira Y; Nakamura T; Koike H; Katsuno M; Hattori N; Tanaka F; Yamamoto M; Sobue G
    Neurology; 2009 Oct; 73(17):1348-52. PubMed ID: 19776380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
    Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
    Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.